TrialJournal of the National Cancer Institute2021

Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Marco Bandini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.